# Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

> **NCT02716805** · PHASE1 · TERMINATED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 6 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Tremelimumab
- **DRUG:** Durvalumab
- **BIOLOGICAL:** Prevnar-13
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT02716805
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-13
- **Primary completion:** 2018-02-16
- **Final completion:** 2018-02-16
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** FDA placed on partial hold due to additional data
- **Last updated:** 2022-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716805, "Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02716805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*